Fig. 2From: The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trialsThe effect of thymosin α1 on 28-day mortality. A total of 10 studies reported mortality within 28 days, and it included a total of 530 patients and 158 eventsBack to article page